Short-term availability of belimumab pre-filled pen formulation for subcutaneous (SC) administration during the current Covid-19 situation

GSK has agreed with MHRA to temporarily make available a European belimumab pre-filled pen formulation for SC administration, to support existing patients receiving belimumab intravenously & minimise need to attend hospital on a monthly basis. GSK will review after 3 months.

Source:

GlaxoSmithKline